The Limitations of Antibiotic Incentives
This article was originally published in RPM Report
Executive Summary
Congress is on the verge of enacting important new incentives for antibiotic development. At the same time, a federal court ruling on Vancocin generic approvals underscores the importance of doing things the right way.
You may also be interested in...
FDA Reorg Elevates Generic Review Activities
In the two months since the enactment of the Generic Drug User Fee Act, FDA has announced a major recruitment from the brand sector to head its generic drug activities (Gregory Geba), approved one controversial transdermal generic (Watson’s lidocaine topical patch), and elevated the generic review activities to “Super Office” status.
Getting Organized for GDUFA: FDA Elevates Generic Review Activities Under New Director Geba
In the two months since the enactment of the Generic Drug User Fee Act, FDA has announced a major recruitment from the brand sector to head its generic drug activities (Gregory Geba), approved one controversial transdermal generic (Watson’s lidocaine topical patch), and elevated the generic review activities to “Super Office” status.
GAIN Is Great: Now Who Gets the Benefits?
Congress is set on enacting a package of antibiotic development incentives—but needs to sort out how best to define the targets.